These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28708135)

  • 1. Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.
    Shin CH; Lee H; Kim HR; Choi KH; Joung JG; Kim HH
    Cell Death Differ; 2017 Nov; 24(11):1861-1871. PubMed ID: 28708135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
    Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
    Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1.
    Zhou SL; Tang QL; Zhou SX; Ren RZ
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2084-2091. PubMed ID: 30915753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells.
    Wang XH; Lu Y; Liang JJ; Cao JX; Jin YQ; An GS; Ni JH; Jia HT; Li SY
    Biochem Biophys Res Commun; 2016 Sep; 478(2):676-82. PubMed ID: 27498003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
    Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
    Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung cancer by suppressing their common targets.
    Choi KH; Shin CH; Lee WJ; Ji H; Kim HH
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LINC00162 regulates cell proliferation and apoptosis by sponging PAQR4-targeting miR-485-5p.
    Lee WJ; Ji H; Jeong SD; Pandey PR; Gorospe M; Kim HH
    J Cell Physiol; 2022 Jul; 237(7):2943-2960. PubMed ID: 35491694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hnRNPK-regulated PTOV1-AS1 modulates heme oxygenase-1 expression via miR-1207-5p.
    Shin CH; Ryu S; Kim HH
    BMB Rep; 2017 Apr; 50(4):220-225. PubMed ID: 28228215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-1249-3p accelerates the malignancy phenotype of hepatocellular carcinoma by directly targeting HNRNPK.
    Shu H; Hu J; Deng H
    Mol Genet Genomic Med; 2019 Oct; 7(10):e00867. PubMed ID: 31429522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA miR-509 Regulates ERK1/2, the Vimentin Network, and Focal Adhesions by Targeting Plk1.
    Liao G; Wang R; Rezey AC; Gerlach BD; Tang DD
    Sci Rep; 2018 Aug; 8(1):12635. PubMed ID: 30135525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression.
    Zhuang W; Liu C; Hong Y; Zheng Y; Huang M; Tang H; Zhao L; Huang Z; Tu M; Yu L; Chen J; Zhang Y; Chen X; Lin F; Gao Q; Yu C; Huang Y
    J Exp Clin Cancer Res; 2024 Apr; 43(1):123. PubMed ID: 38654325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
    He D; Huang C; Zhou Q; Liu D; Xiong L; Xiang H; Ma G; Zhang Z
    Oncotarget; 2017 Mar; 8(12):20165-20178. PubMed ID: 28423622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hnRNPK-regulated LINC00263 promotes malignant phenotypes through miR-147a/CAPN2.
    Lee WJ; Shin CH; Ji H; Jeong SD; Park MS; Won HH; Pandey PR; Tsitsipatis D; Gorospe M; Kim HH
    Cell Death Dis; 2021 Mar; 12(4):290. PubMed ID: 33731671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
    J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.
    Akdeli N; Riemann K; Westphal J; Hess J; Siffert W; Bachmann HS
    Mol Cancer; 2014 Apr; 13():87. PubMed ID: 24767679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A miR-361-5p/ ORC6/ PLK1 axis regulates prostate cancer progression.
    Liu Z; Zhang Y; Yu L; Zhang Z; Li G
    Exp Cell Res; 2024 Jul; 440(1):114130. PubMed ID: 38885805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNA-mediated regulation of splicing factors SRSF1, SRSF2 and hnRNP A1 in context of their alternatively spliced 3'UTRs.
    Sokół E; Kędzierska H; Czubaty A; Rybicka B; Rodzik K; Tański Z; Bogusławska J; Piekiełko-Witkowska A
    Exp Cell Res; 2018 Feb; 363(2):208-217. PubMed ID: 29331391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
    Zhang H; Zhang K; Xu Z; Chen Z; Wang Q; Wang C; Cui J
    BMC Cancer; 2021 Feb; 21(1):163. PubMed ID: 33588776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.
    Qu Y; Zhang H; Duan J; Liu R; Deng T; Bai M; Huang D; Li H; Ning T; Zhang L; Wang X; Ge S; Zhou L; Zhong B; Ying G; Ba Y
    Oncotarget; 2016 May; 7(22):33286-96. PubMed ID: 27120811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.